INAB
IN8bio, Inc.
Biotechnology
Market Cap$6M
5Y Perf.-99.5%
Build Your Comparison
Side-by-side financial analysisINAB
ADCT
Try popular comparisons:
Stock Comparison
INAB vs ADCT
Revenue, margins, valuation, and 5-year total return — side by side.
ADCT
ADC Therapeutics S.A.
Biotechnology
Market Cap$127M
5Y Perf.-95.3%
INAB vs ADCT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  INAB |  ADCT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $6M | $127M |
| Revenue (TTM) | $0.00 | $79M |
| Net Income (TTM) | $-19M | $-137M |
| Gross Margin | — | 90.7% |
| Operating Margin | — | -149.6% |
| Total Debt | $3M | $439M |
| Cash & Equiv. | $27M | $261M |
INAB vs ADCT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
INAB
ADCT
| Stock | Jul 21 | Jun 26 | Return |
|---|---|---|---|
| IN8bio, Inc. (INAB) | 100 | 0.5 | -99.5% |
| ADC Therapeutics S.… (ADCT) | 100 | 4.7 | -95.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: INAB vs ADCT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: INAB leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. ADC Therapeutics S.A. is the stronger pick specifically for capital preservation and lower volatility and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
🥇INAB emerged as the overall leader. Track its performance:
INAB
IN8bio, Inc.
The Growth Leader
INAB carries the broadest edge in this set and is the clearest fit for growth and quality.
- 32.1% revenue growth vs ADCT's 14.9%
- 1.3% margin vs ADCT's -173.0%
- -37.6% vs ADCT's -70.5%
Best for: growth and quality
ADCT
ADC Therapeutics S.A.
The Income Pick
ADCT is the clearest fit if your priority is income & stability and growth exposure.
- beta 1.84
- Rev growth 14.9%, EPS growth 30.9%, 3Y rev CAGR -27.1%
- -96.6% 10Y total return vs INAB's -99.5%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  INAB | 32.1% revenue growth vs ADCT's 14.9% |
| Quality / Margins | INAB | 1.3% margin vs ADCT's -173.0% |
| Stability / Safety |  ADCT | Beta 1.84 vs INAB's 1.89 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | INAB | -37.6% vs ADCT's -70.5% |
| Efficiency (ROA) | ADCT | -44.7% ROA vs INAB's -80.2% |
INAB vs ADCT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
INAB vs ADCT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLADCTLAGGINGINAB
INABIN8bio, Inc.
1leads
ADCTADC Therapeutics S.A.
3leads
6 Total Categories
CATEGORYLEADERvs INABMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ADCT1/1
Valuation MetricsMultiples, price ratios, and targets
ADCT1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
INAB3/5
Total Returns1Y, 3Y, 5Y total returns with dividends
ADCT4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ADCT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ADCT and INAB operate at a comparable scale, with $79M and $0 in trailing revenue.
| Metric | INABIN8bio, Inc. | ADCTADC Therapeutics … |
|---|---|---|
| RevenueTrailing 12 months | $0 | $79M |
| EBITDAEarnings before interest/tax | -$17M | -$117M |
| Net IncomeAfter-tax profit | -$19M | -$137M |
| Free Cash FlowCash after capex | -$15M | -$115M |
| Gross MarginGross profit ÷ Revenue | — | +90.7% |
| Operating MarginEBIT ÷ Revenue | — | -149.6% |
| Net MarginNet income ÷ Revenue | — | -173.0% |
| FCF MarginFCF ÷ Revenue | — | -144.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -9.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.9% | +41.7% |
ADCT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
ADCT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | INABIN8bio, Inc. | ADCTADC Therapeutics … |
|---|---|---|
| Market CapShares × price | $6M | $127M |
| Enterprise ValueMkt cap + debt − cash | -$18M | $304M |
| Trailing P/EPrice ÷ TTM EPS | -0.31x | -0.89x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 1.56x |
| Price / BookPrice ÷ Book value/share | 0.22x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
ADCT leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
INAB leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), INAB scores 5/9 vs ADCT's 4/9, reflecting solid financial health.
| Metric | INABIN8bio, Inc. | ADCTADC Therapeutics … |
|---|---|---|
| ROE (TTM)Return on equity | -96.4% | — |
| ROA (TTM)Return on assets | -80.2% | -44.7% |
| ROICReturn on invested capital | -2.6% | — |
| ROCEReturn on capital employed | -84.5% | -43.8% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.10x | — |
| Net DebtTotal debt minus cash | -$24M | $178M |
| Cash & Equiv.Liquid assets | $27M | $261M |
| Total DebtShort + long-term debt | $3M | $439M |
| Interest CoverageEBIT ÷ Interest expense | — | -1.72x |
INAB leads this category, winning 3 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
ADCT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ADCT five years ago would be worth $433 today (with dividends reinvested), compared to $46 for INAB. Over the past 12 months, INAB leads with a -37.6% total return vs ADCT's -70.5%. The 3-year compound annual growth rate (CAGR) favors ADCT at -24.2% vs INAB's -71.3% — a key indicator of consistent wealth creation.
| Metric | INABIN8bio, Inc. | ADCTADC Therapeutics … |
|---|---|---|
| YTD ReturnYear-to-date | -43.9% | -71.7% |
| 1-Year ReturnPast 12 months | -37.6% | -70.5% |
| 3-Year ReturnCumulative with dividends | -97.6% | -56.5% |
| 5-Year ReturnCumulative with dividends | -99.5% | -95.7% |
| 10-Year ReturnCumulative with dividends | -99.5% | -96.6% |
| CAGR (3Y)Annualised 3-year return | -71.3% | -24.2% |
ADCT leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — INAB and ADCT each lead in 1 of 2 comparable metrics.
Risk & Volatility
ADCT is the less volatile stock with a 1.84 beta — it tends to amplify market swings less than INAB's 1.89 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. INAB currently trades 50.5% from its 52-week high vs ADCT's 20.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | INABIN8bio, Inc. | ADCTADC Therapeutics … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.89x | 1.84x |
| 52-Week HighHighest price in past year | $2.73 | $4.97 |
| 52-Week LowLowest price in past year | $1.17 | $0.78 |
| % of 52W HighCurrent price vs 52-week peak | +50.5% | +20.0% |
| RSI (14)Momentum oscillator 0–100 | 38.9 | 14.8 |
| Avg Volume (50D)Average daily shares traded | 62K | 1.8M |
Evenly matched — INAB and ADCT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | INABIN8bio, Inc. | ADCTADC Therapeutics … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | — | $3.50 |
| # AnalystsCovering analysts | — | 12 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ADCT leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). INAB leads in 1 (Profitability & Efficiency). 1 tied.
Best OverallADC Therapeutics S.A. (ADCT)Leads 3 of 6 categories
Loading custom metrics...
INAB vs ADCT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is INAB or ADCT a better buy right now?
Analysts rate ADC Therapeutics S.
A. (ADCT) a "Hold" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — INAB or ADCT?
Over the past 5 years, ADC Therapeutics S.
A. (ADCT) delivered a total return of -95. 7%, compared to -99. 5% for IN8bio, Inc. (INAB). Over 10 years, the gap is even starker: ADCT returned -96. 6% versus INAB's -99. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — INAB or ADCT?
By beta (market sensitivity over 5 years), ADC Therapeutics S.
A. (ADCT) is the lower-risk stock at 1. 84β versus IN8bio, Inc. 's 1. 89β — meaning INAB is approximately 3% more volatile than ADCT relative to the S&P 500.
04Which is growing faster — INAB or ADCT?
On earnings-per-share growth, the picture is similar: ADC Therapeutics S.
A. grew EPS 30. 9% year-over-year, compared to -678. 9% for IN8bio, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — INAB or ADCT?
IN8bio, Inc.
(INAB) is the more profitable company, earning 0. 0% net margin versus -175. 3% for ADC Therapeutics S. A. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INAB leads at 0. 0% versus -133. 2% for ADCT. At the gross margin level — before operating expenses — ADCT leads at 90. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — INAB or ADCT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is INAB or ADCT better for a retirement portfolio?
For long-horizon retirement investors, ADC Therapeutics S.
A. (ADCT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. IN8bio, Inc. (INAB) carries a higher beta of 1. 89 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ADCT: -96. 6%, INAB: -99. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between INAB and ADCT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.